← Books, chapters & reports

FROM THE PURSER BOOKSHELF · CHAPTER GUIDE

Homocysteine and cardiovascular risk

Learn the difference between a cardiovascular risk marker and a treatment that prevents events.

Based on teaching by Dan Purser, MD. How we prepare these guides

Educational summary

Why this matters

Learn the difference between a cardiovascular risk marker and a treatment that prevents events.

How the pieces connect

Blood-vessel function, clotting, and inflammation may relate to risk. Compare studies of risk with trials that measure heart attacks or strokes.

Association is not the same as prevention

An observational study can find that higher homocysteine accompanies greater cardiovascular risk. A treatment study asks a different question: does an intervention reduce events? Differences in study design, underlying illness and the chosen outcome matter. Read a reported change in homocysteine beside the actual cardiovascular outcomes, rather than assuming one is a substitute for the other. Risk assessment also extends beyond a single metabolic marker.

Keep in mind

Lowering homocysteine has usually not prevented heart attacks or strokes in treatment studies. Ask whether testing this marker would help with your own care.

A question for your next conversation

Did the intervention improve health outcomes, or only the laboratory number?

BUILD YOUR UNDERSTANDING

A few concepts, made clearer.

MTHFR

Makes an enzyme that helps produce a form of folate used in the processing of homocysteine. Common variants are different from rare variants that cause severe MTHFR deficiency.

Read the full reference

LET YOUR CURIOSITY LEAD

One idea opens another.

Choose a subject to find the related teaching across videos, articles, courses and references.